Supporting the

Neuroendocrine Cancer Community

Radionuclide therapy effective in high-grade neuroendocrine neoplasms

Jul 23, 2019

Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 66th Annual Meeting.

[npfButton size=“small” text=”Find out more” href=”″ background-colour=”#f06124″ text-colour=”#ffffff”]